Literature DB >> 27566306

A new monoclonal antibody (Cox mAB 31A2) detects VP1 protein of coxsackievirus B3 with high sensitivity and specificity.

Nicole Ettischer-Schmid1, Andrea Normann2, Martina Sauter1, Lisa Kraft1,3, Hubert Kalbacher3, Reinhard Kandolf1, Bertram Flehmig2, Karin Klingel4.   

Abstract

Human enteroviruses, e.g. coxsackieviruses, induce a variety of severe acute and chronic forms of disease, including myocarditis, meningitis and diabetes mellitus type 1. To visualize enterovirus infection with a diagnostic intent, many studies have applied a commercially available antibody (anti-CVB5 VP1, clone 5-D8/1, Dako, Hamburg, Germany) that identifies VP1 of different enteroviral serotypes. Many antibodies, however, have been found to bind non-specifically to proteins of cardiomyocytes and in the interstitial space, resulting in non-specific staining in immunohistochemistry. In this paper we show that the anti-CVB5 VP1 antibody, recognizing VP1 of coxsackieviruses and widely used in diagnostics and research, shows strong cross-reactivity with cellular proteins in the heart (and pancreas) of humans and mice, which calls for a more specific antibody to be used for diagnostic purposes. We observed by Western blot analyses of lysates from human heart tissue samples and HeLa cells two cross-reactive bands when using clone 5-D8/1. Peptide mass fingerprinting (MALDI-TOF) identified these proteins as creatine kinase (B-type) and tubulin, confirming that this mAb detects cellular proteins in addition to viral VP1. In order to overcome the problems of false positive VP1 staining we generated a new highly specific and sensitive monoclonal antibody (Cox mAB 31A2) that recognizes VP1 from CVB3. The new antibody was characterized and was found to function well in immunohistochemistry, immunofluorescence staining, Western blotting, ELISA and FACS analyses.

Entities:  

Keywords:  Coxsackievirus B3; Diagnostics; Monoclonal antibody; Myocarditis; VP1

Mesh:

Substances:

Year:  2016        PMID: 27566306     DOI: 10.1007/s00428-016-2008-8

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  30 in total

1.  VZV, temporal arteritis, and clinical practice: False positive immunohistochemical detection due to antibody cross-reactivity.

Authors:  David J Pisapia; Ehud Lavi
Journal:  Exp Mol Pathol       Date:  2015-12-11       Impact factor: 3.362

2.  Characterization of the recognition site and diagnostic potential of an enterovirus group-reactive monoclonal antibody.

Authors:  A Samuelson; M Forsgren; M Sällberg
Journal:  Clin Diagn Lab Immunol       Date:  1995-05

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Clinical and research application of an enterovirus group-reactive monoclonal antibody.

Authors:  G E Yousef; G F Mann; I N Brown; J F Mowbray
Journal:  Intervirology       Date:  1987       Impact factor: 1.763

Review 5.  Production of monoclonal antibodies: strategy and tactics.

Authors:  S F de StGroth; D Scheidegger
Journal:  J Immunol Methods       Date:  1980       Impact factor: 2.303

6.  Expression of coxsackievirus B3 capsid proteins in Escherichia coli and generation of virus-specific antisera.

Authors:  S Werner; W M Klump; H Schönke; P H Hofschneider; R Kandolf
Journal:  DNA       Date:  1988-06

7.  Evaluation of the fidelity of immunolabelling obtained with clone 5D8/1, a monoclonal antibody directed against the enteroviral capsid protein, VP1, in human pancreas.

Authors:  Sarah J Richardson; Pia Leete; Shalinee Dhayal; Mark A Russell; Maarit Oikarinen; Jutta E Laiho; Emma Svedin; Katharina Lind; Therese Rosenling; Nora Chapman; Adrian J Bone; Alan K Foulis; Gun Frisk; Malin Flodstrom-Tullberg; Didier Hober; Heikki Hyoty; Noel G Morgan
Journal:  Diabetologia       Date:  2013-11-05       Impact factor: 10.122

8.  Ongoing enterovirus-induced myocarditis is associated with persistent heart muscle infection: quantitative analysis of virus replication, tissue damage, and inflammation.

Authors:  K Klingel; C Hohenadl; A Canu; M Albrecht; M Seemann; G Mall; R Kandolf
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-01       Impact factor: 11.205

Review 9.  Molecular pathology of inflammatory cardiomyopathy.

Authors:  Karin Klingel; Martina Sauter; C Thomas Bock; Gudrun Szalay; Jens-Jörg Schnorr; Reinhard Kandolf
Journal:  Med Microbiol Immunol       Date:  2003-08-14       Impact factor: 3.402

10.  Cytotoxic and viral neutralizing antibodies crossreact with streptococcal M protein, enteroviruses, and human cardiac myosin.

Authors:  M W Cunningham; S M Antone; J M Gulizia; B M McManus; V A Fischetti; C J Gauntt
Journal:  Proc Natl Acad Sci U S A       Date:  1992-02-15       Impact factor: 11.205

View more
  3 in total

1.  Large enteroviral vaccination studies to prevent type 1 diabetes should be well founded and rely on scientific evidence.

Authors:  Oskar Skog; Karin Klingel; Merja Roivainen; Olle Korsgren
Journal:  Diabetologia       Date:  2019-02-27       Impact factor: 10.122

2.  A novel rat CVB1-VP1 monoclonal antibody 3A6 detects a broad range of enteroviruses.

Authors:  Niila V V Saarinen; Jutta E Laiho; Sarah J Richardson; Marie Zeissler; Virginia M Stone; Varpu Marjomäki; Tino Kantoluoto; Marc S Horwitz; Amirbabak Sioofy-Khojine; Anni Honkimaa; Minna M Hankaniemi; Malin Flodström-Tullberg; Heikki Hyöty; Vesa P Hytönen; Olli H Laitinen
Journal:  Sci Rep       Date:  2018-01-08       Impact factor: 4.379

Review 3.  Enteroviral infections in the pathogenesis of type 1 diabetes: new insights for therapeutic intervention.

Authors:  Sarah J Richardson; Noel G Morgan
Journal:  Curr Opin Pharmacol       Date:  2018-07-29       Impact factor: 5.547

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.